PROSTATE CANCER METASTATIC CASTRATION RESISTANT Clinical Trials

44 clinical trials for PROSTATE CANCER METASTATIC CASTRATION RESISTANT across international registries, including 26 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A PHASE III, MULTICENTRE, RANDOMISED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AZD2265 (FPI-2265) 225AC-PSMA-I&T COMPARED WITH STANDARD OF CARE IN PATIENTS WITH PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (VECTRA-01) — RECRUITING · PHASE3
• A PHASE 3, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF XALURITAMIG PLUS ABIRATERONE VERSUS INVESTIGATOR’S CHOICE IN PARTICIPANTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER — RECRUITING · PHASE3
• A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF PASRITAMIG (JNJ-78278343), A T-CELL-REDIRECTING AGENT TARGETING HUMAN KALLIKREIN 2, WITH DOCETAXEL VERSUS DOCETAXEL FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER — RECRUITING · PHASE3
• Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) — RECRUITING · PHASE2
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PASRITAMIG (JNJ-78278343), A T-CELL-REDIRECTING AGENT TARGETING HUMAN KALLIKREIN 2, + BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER — RECRUITING · PHASE3
• Liquid Biopsy Under PSMA Radioligand Therapy — RECRUITING
• A PHASE 1/2 PLATFORM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IFINATAMAB DERUXTECAN AS MONOTHERAPY OR IN COMBINATION WITH OTHER TREATMENTS IN PARTICIPANTS WITH PROSTATE CANCER — RECRUITING · PHASE1
• A PHASE 1 OPEN-LABEL, FIRST-IN-HUMAN, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF ACTINIUM-225-MACROPA-PELGIFATAMAB (BAY 3546828) IN PARTICIPANTS WITH ADVANCED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) — RECRUITING · PHASE1
• A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF OPEVESOSTAT VERSUS ALTERNATIVE ABIRATERONE ACETATE OR ENZALUTAMIDE IN PARTICIPANTS WITH METASTATIC CASTRATIONRESISTANT PROSTATE CANCER (MCRPC) THAT PROGRESSED ON OR AFTER PRIOR TREATMENT WITH ONE NEXT- GENERATION HORMONAL AGENT (NHA) (OMAHA-004) — RECRUITING · PHASE3
• A PHASE 3, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF XALURITAMIG VS CABAZITAXEL OR SECOND ANDROGEN RECEPTOR DIRECTED THERAPY IN SUBJECTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH CHEMOTHERAPY — RECRUITING · PHASE3
• A PHASE 1 OPEN-LABEL, FIRST-IN-HUMAN, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF 225ACPSMA-TRILLIUM IN PARTICIPANTS WITH ADVANCED METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) — RECRUITING · PHASE1
• A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF MK-5684 VERSUS ALTERNATIVE ABIRATERONE ACETATE OR ENZALUTAMIDE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH NEXT-GENERATION HORMONAL AGENT (NHA) AND TAXANE-BASED CHEMOTHERAPY — RECRUITING · PHASE3
• A PHASE 1B STUDY OF EPI-7386, AN INHIBITOR OF THE ANDROGEN RECEPTOR N-TERMINAL DOMAIN, IN COMBINATION WITH ABIRATERONE ACETATE PLUS PREDNISONE, OR APALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) — RECRUITING · PHASE1
• A RANDOMIZED PHASE II STUDY OF 177LU-PSMA-617 VS DOCETAXEL IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND PSMA-POSITIVE DISEASE — RECRUITING · PHASE2
• A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF ORAL EPI-7386 AS A SINGLE AGENT AND IN COMBINATION WITH SECOND-GENERATION ANTIANDROGENS IN PATIENTS WITH ADVANCED PROSTATE CANCER — RECRUITING · PHASE1
• A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF PROSTATE SPECIFIC MEMBRANE ANTIGEN HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER AMG 160 IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER — RECRUITING · PHASE1
• TRIPLE-TRACER MOLECULAR IMAGING USING 18F-FDG, 68GA-PSMA AND 68GA-OCTREOTATE TO CHARACTERIZE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) AND EVALUATE ELIGIBILITY FOR RADIONUCLIDE THERAPIES — RECRUITING
• "A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PEMBROLIZUMAB (MK-3475) PLUS DOCETAXEL PLUS PREDNISONE VERSUS PLACEBO PLUS DOCETAXEL PLUS PREDNISONE IN PARTICIPANTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE PROGRESSED ON A NEXT GENERATION HORMONAL AGENT (NHA) (KEYNOTE- 921)." — RECRUITING · PHASE3
• EFFICACY AND SAFETY OF I-131-1095 RADIOTHERAPY IN COMBINATION WITH ENZALUTAMIDE IN MCRPC PATIENTS WHO ARE 18F-DCFPYL PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-AVID, CHEMOTHERAPY-NAIVE, AND PROGRESSED ON ABIRATERNONE — RECRUITING
• RANDOMIZED PHASE II STUDY OF DOCETAXEL VERSUS CABAZITAXEL POST ABIRATERONE OR ENZALUTAMIDE PROGRESSION. — RECRUITING · PHASE2
• A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF NIRAPARIB IN COMBINATION WITH ABIRATERONE ACETATE AND PREDNISONE VERSUS ABIRATERONE ACETATE AND PREDNISONE FOR TREATMENT OF SUBJECTS WITH METASTATIC PROSTATE CANCER — RECRUITING · PHASE3
• TRITON3: A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE 3 STUDY OF RUCAPARIB VERSUS PHYSICIAN¿S CHOICE OF THERAPY FOR PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY — RECRUITING · PHASE3
• PHASE IB/II TRIAL OF PEMBROLIZUMAB (MK-3475) COMBINATION THERAPIES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) (KEYNOTE-365) — RECRUITING · PHASE1
• A PHASE II STUDY OF DURVALUMAB (MEDI4736) WITH OR WITHOUT TREMELIMUMAB IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER — RECRUITING · PHASE2
• PHASE II TRIAL OF PEMBROLIZUMAB (MK-3475) IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH CHEMOTHERAPY (KEYNOTE-199) — RECRUITING · PHASE2
• BIOMARKERS OF ANDROGEN RESPONSE AND RESISTANCE IN EVOLUTION DURING A RISING PSA — RECRUITING
• PSMACTION: A PHASE II/III, OPEN-LABEL, INTERNATIONAL, MULTICENTER, RANDOMIZED STUDY OF AAA817 VERSUS STANDARD OF CARE IN THE TREATMENT OF ADULT PARTICIPANTS WITH PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO PROGRESSED ON OR AFTER [177LU]LU-PSMA TARGETED THERAPY — NOT_YET_RECRUITING · PHASE2
• A PHASE 3 RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RISVUTATUG REZETECAN, A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (EMBOLD PROSTATE-302) — NOT_YET_RECRUITING · PHASE3
• Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects — ACTIVE_NOT_RECRUITING · PHASE2
• External Beam and Radioligand Radiotherapy for mCRPC — NOT_YET_RECRUITING · PHASE2
• A PHASE 1/2 DOSE ESCALATION TRIAL WITH ADMINISTRATION SCHEDULE EXPLORATION EVALUATING SINGLE AGENT TD001, A PSMA-TARGETED ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH PSMA-EXPRESSING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER — NOT_YET_RECRUITING · PHASE1
• A PHASE 1 FIRST-IN-HUMAN STUDY EVALUATING SAFETY, PHARMACOKINETICS, AND EFFICACY OF ABBV-969 IN ADULT SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER — NOT_YET_RECRUITING · PHASE1
• A PHASE 2/3, RANDOMIZED, OPEN-LABEL, STUDY OF MGC018 VERSUS ANDROGEN RECEPTOR AXIS-TARGETED THERAPY (ABIRETERONE OR ENZALUTAMIDE) IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER — NOT_YET_RECRUITING · PHASE2
• A PHASE 2 TRIAL OF SRF617 IN COMBINATION WITH AB928 (ETRUMADENANT) AND AB122 (ZIMBERELIMAB) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER — COMPLETED · PHASE2
• PROCADE: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, NON-INFERIORITY, EFFICACY AND SAFETY STUDY OF ORAL HC-1119 VERSUS ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) — COMPLETED · PHASE3
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF NIVOLUMAB OR PLACEBO IN COMBINATION WITH DOCETAXEL, IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CHECKMATE 7DX: CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVALUATION 7DX). — COMPLETED · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL OF PEMBROLIZUMAB (MK-3475) PLUS ENZALUTAMIDE VERSUS PLACEBO PLUS ENZALUTAMIDE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) (KEYNOTE-641) — COMPLETED · PHASE3
• Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL) — TERMINATED · PHASE2
• A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE RESISTANT PROSTATE CANCER — COMPLETED · PHASE3
• TRITON2: A MULTICENTER, OPEN-LABEL PHASE 2 STUDY OF RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY — COMPLETED · PHASE2
• A PHASE 2, OPEN LABEL, 2 ARM, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE-BASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT (ENZALUTAMIDE AND/OR ABIRATERONE ACETATE/PREDNISONE). — NOT_YET_RECRUITING · PHASE2
• A PHASE 2 EFFICACY AND SAFETY STUDY OF NIRAPARIB IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND DNA-REPAIR ANOMALIES. — COMPLETED · PHASE2
• ARMOR3-SV: A PHASE 3, RANDOMIZED, OPEN LABEL, MULTICENTER, CONTROLLED STUDY OF GALETERONE COMPARED TO ENZALUTAMIDE IN MEN EXPRESSING ANDROGEN RECEPTOR SPLICE VARIANT-7 MRNA (AR-V7) METASTATIC (M1) CASTRATE RESISTANT PROSTATE CANCER (CRPC) — COMPLETED · PHASE3
• A PHASE II, RANDOMIZED, MULTI-CENTER STUDY OF CABAZITAXEL VERSUS ABIRATERONE OR ENZALUTAMIDE IN POOR PROGNOSIS-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER — COMPLETED · PHASE2

Refine this search